Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR(−)/HER2(+) breast cancers

HER2-positive (HER2(+)) breast adenocarcinomas are a heterogeneous group in which hormone receptor (HR) status influences therapeutic decisions and patient outcome. By combining genome-wide RNAi screens with regulatory network analysis, we identified STAT3 as a critically activated master regulator...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Genes Dev
Autors principals: Rodriguez-Barrueco, Ruth, Yu, Jiyang, Saucedo-Cuevas, Laura P., Olivan, Mireia, Llobet-Navas, David, Putcha, Preeti, Castro, Veronica, Murga-Penas, Eva M., Collazo-Lorduy, Ana, Castillo-Martin, Mireia, Alvarez, Mariano, Cordon-Cardo, Carlos, Kalinsky, Kevin, Maurer, Matthew, Califano, Andrea, Silva, Jose M.
Format: Artigo
Idioma:Inglês
Publicat: Cold Spring Harbor Laboratory Press 2015
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4536311/
https://ncbi.nlm.nih.gov/pubmed/26227964
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/gad.262642.115
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars